|
Apr 25
|
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
|
|
Mar 12
|
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
|
|
Mar 11
|
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Feb 24
|
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
|
|
Feb 12
|
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch
|
|
Oct 4
|
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
|
|
Jun 25
|
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
|
|
May 3
|
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 24
|
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 23
|
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
|
|
Apr 15
|
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
|
|
Apr 5
|
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
|
|
Apr 4
|
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
|
|
Mar 12
|
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
|
|
Mar 9
|
Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 7
|
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 7
|
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 6
|
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
|
|
Mar 5
|
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
|
|
Dec 14
|
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
|